4-Hydroxy-3-jodo-5-methoxybenzylidenmalononitril | 27389-84-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-Hydroxy-3-jodo-5-methoxybenzylidenmalononitril
• 英文别名: 3-methoxy-4-hydroxy-5-iodobenzylidene malononitrile；2-[(4-Hydroxy-3-iodo-5-methoxyphenyl)methylene]malononitrile；2-[(4-hydroxy-3-iodo-5-methoxyphenyl)methylidene]propanedinitrile
• CAS: 27389-84-0
• 化学式: C₁₁H₇IN₂O₂
• mdl: MFCD00814646
• 分子量: 326.093
• InChiKey: BZIXGOBJBFWPTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  77
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氰基-N-(苯基甲基)-乙酰胺 、 4-Hydroxy-3-jodo-5-methoxybenzylidenmalononitril 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 以41%的产率得到AG 1505
  参考文献：
  名称：

  Quinazoline compounds and compositions thereof for the treatment of

  摘要：

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，特别是KDR/FLK-1受体信号传导，以调节和/或调节血管生成和血管新生。该发明部分基于KDR/FLK-1酪氨酸激酶受体表达与内皮细胞相关，并确定血管内皮生长因子（VEGF）为FLK-1的高亲和力配体的论证。这些结果表明KDR/FLK-1在血管生成和血管新生过程中的信号系统中起着重要作用。描述了表达FLK-1的宿主细胞的工程化，以及利用表达的FLK-1评估和筛选参与FLK-1调节的VEGF的药物和类似物，无论是通过激动剂还是拮抗剂活性。该发明还涉及使用所披露的化合物治疗与血管生成和血管新生相关的疾病，包括癌症、糖尿病、血管瘤和卡波西肉瘤。

  公开号：

  US05792771A1
• 作为产物：
  描述：

  5-碘香兰素 、 丙二腈 在 三乙胺 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 4-Hydroxy-3-jodo-5-methoxybenzylidenmalononitril
  参考文献：
  名称：

  合成，体外和计算机筛选2-氨基-4-芳基-6-（苯硫基）吡啶-3,5-二腈作为新型α-葡萄糖苷酶抑制剂。

  摘要：

  抑制α-葡萄糖苷酶对于治疗糖尿病（DM）至关重要。除许多有机支架外，以前已报道吡啶基化合物具有广泛的生物活性。本研究报告了一系列基于吡啶的合成类似物，通过体外，动力学和计算机模拟研究评估了其对α-葡萄糖苷酶抑制的潜力。为此目的，合成了2-氨基-4-芳基-6-（苯硫基）吡啶-3，5-二腈1-28，并进行了体外筛选。与标准阿卡波糖（IC50 = 750±10 µM）相比，包括1-3、7、9、11-14和16在内的几种类似物显示出许多潜在的抑制作用增加。有趣的是，化合物7（IC50 = 55.6±0.3 µM）的抑制强度是标准阿卡波糖的13倍。对最有效分子7的动力学研究揭示了竞争型抑制机制。在计算机上进行了研究以检查配体（化合物7）与α-葡糖苷酶的活性位点残基的结合模式。

  DOI：

  10.1016/j.bioorg.2020.103879

文献信息

• Quinazoline compounds and compositions thereof for the treatment of
  申请人：Sugen, Inc.

  公开号：US05792771A1

  公开（公告）日：1998-08-11

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction and particularly KDR/FLK-1 receptor signal transduction in order to regulate and/or modulate vasculogenesis and angiogenesis. The invention is based, in part, on the demonstration that KDR/FLK-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of FLK-1. These results indicate a major role for KDR/FLK-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express FLK-1 and the uses of expressed FLK-1 to evaluate and screen for drugs and analogs of VEGF involved in FLK-1 modulation by either agonist or antagonist activities is also described. The invention also relates to the use of the disclosed compounds in the treatment of disorders, including cancer, diabetes, hemangioma and Kaposi's sarcoma, which are related to vasculogenesis and angiogenesis.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，特别是KDR/FLK-1受体信号传导，以调节和/或调节血管生成和血管新生。该发明部分基于KDR/FLK-1酪氨酸激酶受体表达与内皮细胞相关，并确定血管内皮生长因子（VEGF）为FLK-1的高亲和力配体的论证。这些结果表明KDR/FLK-1在血管生成和血管新生过程中的信号系统中起着重要作用。描述了表达FLK-1的宿主细胞的工程化，以及利用表达的FLK-1评估和筛选参与FLK-1调节的VEGF的药物和类似物，无论是通过激动剂还是拮抗剂活性。该发明还涉及使用所披露的化合物治疗与血管生成和血管新生相关的疾病，包括癌症、糖尿病、血管瘤和卡波西肉瘤。
• Compounds for the treament of disorders related to vasculogenesis and/or
  申请人：Sugen Inc.

  公开号：US05849742A1

  公开（公告）日：1998-12-15

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction and particularly KDR/FLK-1 receptor signal transduction in order to regulate and/or modulate vasculogenesis and angiogenesis. The invention is based, in part, on the demonstration that KDR/FLK-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of FLK-1. These results indicate a major role for KDR/FLX-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express FLK-1 and the uses of expressed FLK-1 to evaluate and screen for drugs and analogs of VEGF involved in FLK-1 modulation by either agonist or antagonist activities is also described. The invention also relates to the use of the disclosed compounds in the treatment of disorders, including cancer, diabetes, hemangioma and Kaposi's sarcoma, which are related to vasculogenesis and angiogenesis.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，特别是KDR/FLK-1受体信号传导，以调节和/或调制血管生成和血管新生。本发明部分基于证明KDR/FLK-1酪氨酸激酶受体表达与内皮细胞相关，并确定血管内皮生长因子（VEGF）为FLK-1的高亲和力配体。这些结果表明KDR/FLX-1在血管生成和血管新生信号系统中具有重要作用。本发明还描述了表达FLK-1的宿主细胞的工程化，以及利用表达的FLK-1评估和筛选参与FLK-1调节的VEGF药物和类似物，包括激动剂或拮抗剂活性。本发明还涉及使用所披露的化合物治疗与血管生成和血管新生相关的疾病，包括癌症、糖尿病、血管瘤和卡波西肉瘤。
• Substituted phenylacrylonitrile compounds and compositions thereof for
  申请人：Yissum Research Development Company of the Hebrew University of Jerusalem

  公开号：US05981569A1

  公开（公告）日：1999-11-09

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction and particularly KDR/FLK-1 receptor signal transduction in order to regulate and/or modulate vasculogenesis and angiogenesis. The invention is based, in part, on the demonstration that KDR/FLK-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of FLK-1. These results indicate a major role for KDR/FLK-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express FLK-1 and the uses of expressed FLK-1 to evaluate and screen for drugs and analogs of VEGF involved in FLK-1 modulation by either agonist or antagonist activities is also described. The invention also relates to the use of the disclosed compounds in the treatment of disorders, including cancer, diabetes, hemangioma and Kaposi's sarcoma, which are related to vasculogenesis and angiogenesis.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，特别是KDR/FLK-1受体信号传导，以调节和/或调制血管生成和血管新生。本发明部分基于KDR/FLK-1酪氨酸激酶受体表达与内皮细胞相关的证明，以及血管内皮生长因子(VEGF)作为FLK-1高亲和力配体的鉴定。这些结果表明，在血管生成和血管新生的信号系统中，KDR/FLK-1起着重要作用。本发明还描述了表达FLK-1的宿主细胞的工程化，以及使用表达的FLK-1评估和筛选参与FLK-1调节的VEGF药物和类似物的作用机制，无论是激动剂还是拮抗剂。本发明还涉及使用所披露的化合物治疗与血管生成和血管新生相关的疾病，包括癌症、糖尿病、血管瘤和卡波西肉瘤。
• COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS
  申请人：Sugen, Inc.

  公开号：EP0748219B1

  公开（公告）日：2005-04-06
• EP0748219A4
  申请人：——

  公开号：EP0748219A4

  公开（公告）日：1999-06-16